Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia
KeywordsSAR-CoV-2 pneumonia, transient leukopenia, remdesivir, baricitinib, dexamethasone
Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness in patients with severe SARS-CoV-2. However; the data regarding the safety and side effects related to this combination therapy are limited to case reports. The purpose of this case report is to highlight a potentially life-threatening side effect of one or all medications mentioned above.
Issue: 2022: Vol 9 No 10 (view)